Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBYN DAWN HARTVICKSON

Allopathic & Osteopathic Physicians Family Medicine

NPI
1679532659
CMS profile
303021
Location
NEWTON, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$813.93

47 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $813.93 47

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBYN DAWN HARTVICKSON

NPI 1679532659 · CMS profile ID 303021

Allopathic & Osteopathic Physicians / Family Medicine

NEWTON, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679532659?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679532659?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679532659?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–47 of 47 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1679532659?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

47 matching records · $813.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 47 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–47 of 47.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer Healthcare Pharmaceuticals Inc. $16.8212/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225569332 CMS
PFIZER INC. $21.8811/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229842444 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.7111/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231992815 CMS
Sumitomo Pharma America, Inc. $19.6211/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176664465 CMS
Bayer Healthcare Pharmaceuticals Inc. $13.5711/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225569330 CMS
PFIZER INC. $16.1911/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229840792 CMS
ABBVIE INC. $17.7811/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202014886 CMS
PFIZER INC. $3.6510/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229754574 CMS
Amgen Inc. $14.8010/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227188146 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.7810/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225569326 CMS
PFIZER INC. $17.2310/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229465653 CMS
Astellas Pharma US Inc $15.2209/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238686165 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.5809/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225569328 CMS
Amgen Inc. $13.8809/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227188144 CMS
ABBVIE INC. $17.5009/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202014884 CMS
Sumitomo Pharma America, Inc. $15.9308/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176664463 CMS
PFIZER INC. $2.7808/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231709701 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.9308/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225569324 CMS
Amgen Inc. $14.2708/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227188148 CMS
Astellas Pharma US Inc $13.8008/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238642661 CMS
AstraZeneca Pharmaceuticals LP $25.1907/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206257830 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.6106/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225569322 CMS
Astellas Pharma US Inc $16.2806/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238642580 CMS
Sumitomo Pharma America, Inc. $21.1406/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176664461 CMS
PFIZER INC. $17.7206/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231339396 CMS
Amgen Inc. $17.8505/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228441280 CMS
Novo Nordisk Inc $14.2605/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188792294 CMS
PFIZER INC. $16.9805/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228936241 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.0404/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225569318 CMS
AstraZeneca Pharmaceuticals LP $19.2004/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207275108 CMS
Amgen Inc. $15.9304/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228441276 CMS
PFIZER INC. $16.5704/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231425557 CMS
PFIZER INC. $19.0204/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231500391 CMS
Amgen Inc. $15.3803/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228441278 CMS
Cranial Technologies, Inc $19.9303/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246299294 CMS
PFIZER INC. $14.6803/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231535749 CMS
Astellas Pharma US Inc $15.6703/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238706040 CMS
AstraZeneca Pharmaceuticals LP $14.2602/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206141822 CMS
PFIZER INC. $22.7902/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231633737 CMS
PFIZER INC. $15.5702/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231629913 CMS
ABBVIE INC. $23.1201/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202014882 CMS
ABBVIE INC. $14.1501/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202014880 CMS
AstraZeneca Pharmaceuticals LP $62.1501/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206368897 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.5401/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225569320 CMS
Sumitomo Pharma America, Inc. $21.2601/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176664459 CMS
AstraZeneca Pharmaceuticals LP $15.0401/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206322881 CMS
PFIZER INC. $14.6801/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231125601 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $349.87 24
PY2020 $259.38 18
PY2021 $867.92 59
PY2022 $1,012.70 73
PY2023 $2,574.33 71
PY2024 $862.16 54
PY2025 $813.93 47

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $136,207.90 39
PY2024 Principal investigator $344,898.92 54
PY2023 Principal investigator $702,129.77 95
PY2022 Principal investigator $153,146.27 62
PY2021 Principal investigator $143,310.07 45
PY2020 Principal investigator $223,270.91 168
PY2019 Principal investigator $302,825.41 141

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

168 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $2,106.97 12/31/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721317501
Principal investigator 1 Allergan, Inc. $86.00 12/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721313763
Principal investigator 1 PFIZER INC. $1,063.57 12/17/2020 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 742877113
Principal investigator 1 GlaxoSmithKline, LLC. $1,685.70 12/16/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734922985
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758445
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758447
Principal investigator 1 Merck Sharp & Dohme Corporation $66.50 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758449
Principal investigator 1 Merck Sharp & Dohme Corporation $7.00 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758451
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758453
Principal investigator 1 Merck Sharp & Dohme Corporation $1.52 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758465
Principal investigator 1 Merck Sharp & Dohme Corporation $10.56 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758467
Principal investigator 1 Merck Sharp & Dohme Corporation $11.00 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758469
Principal investigator 1 Merck Sharp & Dohme Corporation $16.16 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758471
Principal investigator 1 Merck Sharp & Dohme Corporation $1,848.00 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758473
Principal investigator 1 Merck Sharp & Dohme Corporation $847.00 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758475
Principal investigator 1 Merck Sharp & Dohme Corporation $9.10 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758477
Principal investigator 1 Merck Sharp & Dohme Corporation $108.90 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758479
Principal investigator 1 Merck Sharp & Dohme Corporation $23.10 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758481
Principal investigator 1 Merck Sharp & Dohme Corporation $47.60 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758483
Principal investigator 1 Merck Sharp & Dohme Corporation $19.36 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758499
Principal investigator 1 Merck Sharp & Dohme Corporation $192.50 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758501
Principal investigator 1 Merck Sharp & Dohme Corporation $2.72 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758503
Principal investigator 1 Merck Sharp & Dohme Corporation $20.40 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758505
Principal investigator 1 Merck Sharp & Dohme Corporation $235.20 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758507
Principal investigator 1 Merck Sharp & Dohme Corporation $26.60 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758533
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758535
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758537
Principal investigator 1 Merck Sharp & Dohme Corporation $4.80 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758539
Principal investigator 1 Merck Sharp & Dohme Corporation $4.90 12/08/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758541
Principal investigator 1 Allergan, Inc. $315.00 12/03/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721310371
Principal investigator 1 Allergan, Inc. $315.00 12/03/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721310549
Principal investigator 1 PFIZER INC. $4,122.02 12/03/2020 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 742876823
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 11/25/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758563
Principal investigator 1 GlaxoSmithKline, LLC. $1,300.50 11/24/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734917959
Principal investigator 1 GlaxoSmithKline, LLC. $1,394.10 11/18/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734917837
Principal investigator 1 Allergan, Inc. $315.00 11/05/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721306601
Principal investigator 1 Allergan, Inc. $371.00 11/05/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721306675
Principal investigator 1 GlaxoSmithKline, LLC. $1,363.50 11/04/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734920289
Principal investigator 1 GlaxoSmithKline, LLC. $110.00 11/04/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734929293
Principal investigator 1 Merck Sharp & Dohme Corporation $30.00 11/02/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758561
Principal investigator 1 Merck Sharp & Dohme Corporation $1,268.82 10/28/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758559
Principal investigator 1 GlaxoSmithKline, LLC. $1,178.10 10/27/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734925829
Principal investigator 1 GlaxoSmithKline, LLC. $1,178.10 10/27/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965524421
Principal investigator 1 GlaxoSmithKline, LLC. $107.40 10/14/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734917835
Principal investigator 1 GlaxoSmithKline, LLC. $107.40 10/14/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965524495
Principal investigator 1 Merck Sharp & Dohme Corporation $9,080.10 10/14/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758565
Principal investigator 1 Allergan, Inc. $700.00 10/08/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721301795
Principal investigator 1 GlaxoSmithKline, LLC. $1,247.40 10/01/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734925215
Principal investigator 1 GlaxoSmithKline, LLC. $1,247.40 10/01/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965524427
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 09/28/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758557
Principal investigator 1 GlaxoSmithKline, LLC. $1,031.40 09/23/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734908999
Principal investigator 1 Merck Sharp & Dohme Corporation $4,353.66 09/23/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758555
Principal investigator 1 Allergan, Inc. $86.00 09/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721296759
Principal investigator 1 SANOFI PASTEUR INC. $7,150.00 09/15/2020 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
VAD00001 Study of a Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers No dispute reported 06/30/2026 744039467
Principal investigator 1 GlaxoSmithKline, LLC. $2,442.60 09/09/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734908983
Principal investigator 1 Allergan, Inc. $86.00 09/03/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721295139
Principal investigator 1 Merck Sharp & Dohme Corporation $210.00 09/02/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758525
Principal investigator 1 Merck Sharp & Dohme Corporation $90.00 09/02/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758527
Principal investigator 1 Merck Sharp & Dohme Corporation $4,353.66 09/02/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758531
Principal investigator 1 Allergan, Inc. $86.00 08/27/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721293961
Principal investigator 1 Allergan, Inc. $5,297.20 08/14/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721290427
Principal investigator 1 GlaxoSmithKline, LLC. $1,597.50 08/12/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734908679
Principal investigator 1 GlaxoSmithKline, LLC. $2,740.50 08/03/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734910987
Principal investigator 1 Allergan, Inc. $700.00 07/30/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721287773
Principal investigator 1 Allergan, Inc. $86.00 07/30/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721287791
Principal investigator 1 Merck Sharp & Dohme Corporation $1,268.82 07/24/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758495
Principal investigator 1 Merck Sharp & Dohme Corporation $30.00 07/24/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758497
Principal investigator 1 Merck Sharp & Dohme Corporation $30.00 07/24/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758521
Principal investigator 1 GlaxoSmithKline, LLC. $1,100.70 07/22/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734910985
Principal investigator 1 Allergan, Inc. $7,945.80 07/17/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721285101
Principal investigator 1 Merck Sharp & Dohme Corporation $13,136.76 07/15/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758523
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 07/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758529
Principal investigator 1 GlaxoSmithKline, LLC. $1,510.20 07/02/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734915845
Principal investigator 1 GlaxoSmithKline, LLC. $1,598.40 07/02/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734921713
Principal investigator 1 GlaxoSmithKline, LLC. $1,216.80 07/01/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734908981
Principal investigator 1 GlaxoSmithKline, LLC. $1,007.10 07/01/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734928633
Principal investigator 1 GlaxoSmithKline, LLC. $1,310.40 06/24/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734901023
Principal investigator 1 GlaxoSmithKline, LLC. $6,435.90 06/10/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734901379
Principal investigator 1 Merck Sharp & Dohme Corporation $3,897.84 06/05/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758457
Principal investigator 1 Allergan, Inc. $925.00 05/21/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721276621
Principal investigator 1 SANOFI PASTEUR INC. $550.00 05/14/2020 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
QHD04 Safety and Immunogenicity of Different Dosages of High Dose Quadrivalent Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in Children 6 months to Less than 5 Years of Age No dispute reported 06/30/2026 744040269
Principal investigator 1 PFIZER INC. $9,000.00 05/12/2020 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 742879469
Principal investigator 1 Merck Sharp & Dohme Corporation $995.40 04/17/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758493
Principal investigator 1 Allergan, Inc. $7,724.45 04/14/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721270129
Principal investigator 1 GlaxoSmithKline, LLC. $1,383.30 04/01/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 734900845
Principal investigator 1 Allergan, Inc. $315.00 03/31/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721267791
Principal investigator 1 Allergan, Inc. $315.00 03/31/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721267923
Principal investigator 1 Allergan, Inc. $86.00 03/26/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721267399
Principal investigator 1 GlaxoSmithKline, LLC. $1,288.80 03/18/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 753908983
Principal investigator 1 GlaxoSmithKline, LLC. $1,288.80 03/18/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965524433
Principal investigator 1 Allergan, Inc. $1,691.95 03/16/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721264525
Principal investigator 1 GlaxoSmithKline, LLC. $2,024.10 03/11/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 753909759
Principal investigator 1 GlaxoSmithKline, LLC. $2,024.10 03/11/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965524417
Principal investigator 1 Merck Sharp & Dohme Corporation $907.50 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758367
Principal investigator 1 Merck Sharp & Dohme Corporation $10.50 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758373
Principal investigator 1 Merck Sharp & Dohme Corporation $102.00 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758375
Principal investigator 1 Merck Sharp & Dohme Corporation $142.50 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758379
Principal investigator 1 Merck Sharp & Dohme Corporation $19.50 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758387
Principal investigator 1 Merck Sharp & Dohme Corporation $412.50 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758411
Principal investigator 1 Merck Sharp & Dohme Corporation $504.00 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758423
Principal investigator 1 Merck Sharp & Dohme Corporation $57.00 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758425
Principal investigator 1 Merck Sharp & Dohme Corporation $742.50 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758433
Principal investigator 1 Merck Sharp & Dohme Corporation $30.00 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758439
Principal investigator 1 Merck Sharp & Dohme Corporation $547.20 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758441
Principal investigator 1 Merck Sharp & Dohme Corporation $3,960.00 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758463
Principal investigator 1 Merck Sharp & Dohme Corporation $49.50 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758487
Principal investigator 1 Merck Sharp & Dohme Corporation $7.50 03/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758489
Principal investigator 1 Allergan, Inc. $86.00 03/05/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721262055
Principal investigator 1 GlaxoSmithKline, LLC. $1,363.50 03/04/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 753908683
Principal investigator 1 GlaxoSmithKline, LLC. $1,363.50 03/04/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965524431
Principal investigator 1 Allergan, Inc. $7,200.00 02/25/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721260947
Principal investigator 1 Allergan, Inc. $1,500.00 02/25/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 721260949
Principal investigator 1 Allergan, Inc. $7,000.00 02/25/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 721260951
Principal investigator 1 Allergan, Inc. $1,500.00 02/25/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC DBA N
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 721260953
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 02/19/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734901505
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 02/19/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734906049
Principal investigator 1 GlaxoSmithKline, LLC. $1,142.10 02/19/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734909537
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 02/19/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965524435
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 02/19/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965524493
Principal investigator 1 GlaxoSmithKline, LLC. $1,142.10 02/19/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965524497
Principal investigator 1 Allergan, Inc. $700.00 02/13/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721256445
Principal investigator 1 GlaxoSmithKline, LLC. $1,236.60 02/12/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734906045
Principal investigator 1 GlaxoSmithKline, LLC. $1,236.60 02/12/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965524429
Principal investigator 1 Allergan, Inc. $700.00 02/11/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
CHRONIC IDIOPATHIC CONSTIPATION (CIC),IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) No dispute reported 06/30/2026 721256261
Principal investigator 1 Merck Sharp & Dohme Corporation $76.00 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758359
Principal investigator 1 Merck Sharp & Dohme Corporation $8.00 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758361
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758369
Principal investigator 1 Merck Sharp & Dohme Corporation $10.40 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758371
Principal investigator 1 Merck Sharp & Dohme Corporation $14.08 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758377
Principal investigator 1 Merck Sharp & Dohme Corporation $16.16 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758381
Principal investigator 1 Merck Sharp & Dohme Corporation $19.36 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758385
Principal investigator 1 Merck Sharp & Dohme Corporation $2,112.00 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758393
Principal investigator 1 Merck Sharp & Dohme Corporation $231.00 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758395
Principal investigator 1 Merck Sharp & Dohme Corporation $26.40 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758399
Principal investigator 1 Merck Sharp & Dohme Corporation $268.80 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758403
Principal investigator 1 Merck Sharp & Dohme Corporation $31.92 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758405
Principal investigator 1 Merck Sharp & Dohme Corporation $4.80 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758407
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758415
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758417
Principal investigator 1 Merck Sharp & Dohme Corporation $5.60 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758419
Principal investigator 1 Merck Sharp & Dohme Corporation $57.12 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758427
Principal investigator 1 Merck Sharp & Dohme Corporation $17.75 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758459
Principal investigator 1 Merck Sharp & Dohme Corporation $968.00 02/10/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758491
Principal investigator 1 SANOFI PASTEUR INC. $15,581.30 01/23/2020 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
QHD04 Safety and Immunogenicity of Different Dosages of High Dose Quadrivalent Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in Children 6 months to Less than 5 Years of Age No dispute reported 06/30/2026 744040209
Principal investigator 1 GlaxoSmithKline, LLC. $1,719.90 01/22/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734911981
Principal investigator 1 GlaxoSmithKline, LLC. $1,719.90 01/22/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965524425
Principal investigator 1 Merck Sharp & Dohme Corporation $74.85 01/22/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758421
Principal investigator 1 Merck Sharp & Dohme Corporation $2,787.30 01/17/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758437
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 01/17/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758455
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 01/16/2020 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
QHD04 Safety and Immunogenicity of Different Dosages of High Dose Quadrivalent Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in Children 6 months to Less than 5 Years of Age No dispute reported 06/30/2026 744040161
Principal investigator 1 SANOFI PASTEUR INC. $1,300.00 01/16/2020 Non-covered Recipient Entity
Alliance For Multispecialty Research,LLC
QHD04 Safety and Immunogenicity of Different Dosages of High Dose Quadrivalent Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in Children 6 months to Less than 5 Years of Age No dispute reported 06/30/2026 744040171
Principal investigator 1 GlaxoSmithKline, LLC. $1,247.40 01/15/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734909533
Principal investigator 1 GlaxoSmithKline, LLC. $1,247.40 01/15/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965524423
Principal investigator 1 Merck Sharp & Dohme Corporation $9,024.60 01/15/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758443
Principal investigator 1 Merck Sharp & Dohme Corporation $847.00 01/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758363
Principal investigator 1 Merck Sharp & Dohme Corporation $9.10 01/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758365
Principal investigator 1 Merck Sharp & Dohme Corporation $1,848.00 01/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758383
Principal investigator 1 Merck Sharp & Dohme Corporation $192.50 01/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758389
Principal investigator 1 Merck Sharp & Dohme Corporation $20.00 01/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758391
Principal investigator 1 Merck Sharp & Dohme Corporation $235.20 01/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758397
Principal investigator 1 Merck Sharp & Dohme Corporation $26.60 01/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758401
Principal investigator 1 Merck Sharp & Dohme Corporation $4.90 01/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758409
Principal investigator 1 Merck Sharp & Dohme Corporation $47.60 01/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758413
Principal investigator 1 Merck Sharp & Dohme Corporation $66.50 01/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758429
Principal investigator 1 Merck Sharp & Dohme Corporation $7.00 01/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758431
Principal investigator 1 Merck Sharp & Dohme Corporation $23.10 01/09/2020 Non-covered Recipient Entity
HEARTLAND RESEARCH ASSOCIATES, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740758461
Principal investigator 1 GlaxoSmithKline, LLC. $1,498.50 01/08/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 734905903
Principal investigator 1 GlaxoSmithKline, LLC. $1,498.50 01/08/2020 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 965524419